Enochian BioSciences Announces Scientific Presentation of Elimination of HBV in Mice with No Evident Toxicity
June 30 2021 - 7:00AM
(NASDAQ: ENOB) – Enochian BioSciences, Inc., a company focused on
gene-modified cellular and immune therapies in infectious diseases
and cancer, today announced that Dr. Serhat Gumrukçu, co-founder
and inventor of Enochian BioSciences and Director of Seraph
Research Institute (SRI), presented data demonstrating daily
reduction of Hepatitis B Virus (HBV) until it could no longer be
detected by the 8th day. No toxicities to the liver or other
tissues were identified. The findings were presented during the
prestigious International Liver Conference, and presentations can
be found (Link to presentations.)
Enochian BioSciences holds the exclusive license
for the proprietary technology. The daily measurements, studies of
various doses of the product, and toxicity are important components
for review by regulatory agencies.
The innovative cellular therapy, known as Hijack
RNA, tricks the viruses to use proteins that are needed to
reproduce, in order to trigger the infected cells to commit suicide
instead of becoming a virus-making factory. On June 21, Enochian
BioSciences announced the acquisition of an exclusive license for
the use of the Hijack RNA approach as a potential way to treat or
prevent any variant of influenza or coronaviruses, including the
one that causes COVID-19 (see news release). A similar approach to
potentially treat or cure HIV is being developed to expand Hijack
RNA as an Enochian BioSciences platform to treat deadly
viruses.
Dr. Mark Dybul, a public health expert in HIV
and Executive Vice Chairperson of the Board of Enochian BioSciences
commented, “The promising data presented by Dr. Gumrukçu builds on
growing evidence that this novel strategy could potentially cure
HBV, a condition which affects approximately 350 million
individuals worldwide. Combined with the promising results from
studies to treat or prevent any coronavirus or influenza virus, the
data also offers hope that Hijack RNA could be a powerful platform
technology to combat some of the most devastating diseases in the
world.”
About Enochian BioSciences,
Inc.Enochian BioSciences, Inc. is a biopharmaceutical
company focused on developing innovative platforms for
gene-modified cellular and immune therapies to potentially cure and
treat deadly diseases. The company’s gene-modified cell and immune
therapy platforms can potentially be applied to multiple
indications, including HIV/AIDS, Hepatitis B, all Corona and
Influenza virsuses, and Oncology. For more information, please
visit Enochianbio.com
About Seraph Research Institute
(SRI)Seraph Research Institute is a Los Angeles-based
non-profit research institution, which runs basic science,
translational and clinical research in pursuit of cures and
effective treatments for chronic viral infections, cancers, and
genetic disorders. For more information, please visit
Seraphinstitute.org
Forward-Looking
StatementsStatements in this press release that are not
strictly historical in nature are forward-looking statements. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties,
including but not limited to the success or efficacy of our
pipeline. All statements other than historical facts are
forward-looking statements, which can be identified by the use of
forward-looking terminology such as “believes,” “plans,” “expects,”
“aims,” “intends,” “potential,” or similar expressions. Actual
events or results may differ materially from those projected in any
of such statements due to various uncertainties, including as set
forth in Enochian BioScience’s most recent Annual Report on Form
10-K filed with the SEC. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. All forward-looking statements are
qualified in their entirety by this cautionary statement, and
Enochian BioSciences undertakes no obligation to revise or update
this press release to reflect events or circumstances after the
date hereof.
Contact: ir@enochianbio.com
Enochian Biosciences (NASDAQ:ENOB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enochian Biosciences (NASDAQ:ENOB)
Historical Stock Chart
From Apr 2023 to Apr 2024